반응식
[OH:1][C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][C:3]=1[S:8][CH3:9].F[C:11]1[CH:16]=[CH:15][C:14](F)=[CH:13][C:12]=1[N+:18]([O-:20])=[O:19].[F:21][C:22]1[CH:28]=[CH:27][C:25]([NH2:26])=[C:24]([O:29][C:30]2[CH:35]=[CH:34][CH:33]=[CH:32][C:31]=2[S:36][CH3:37])[CH:23]=1.[NH2:38][C:39]1[S:40][CH:41]=[CH:42][N:43]=1>>[F:21][C:15]1[CH:14]=[CH:13][C:12]([N+:18]([O-:20])=[O:19])=[C:11]([O:1][C:2]2[CH:7]=[CH:6][CH:5]=[CH:4][C:3]=2[S:8][CH3:9])[CH:16]=1.[F:21][C:22]1[CH:28]=[CH:27][C:25]([NH:26][C:2]([NH:38][C:39]2[S:40][CH:41]=[CH:42][N:43]=2)=[O:1])=[C:24]([O:29][C:30]2[CH:35]=[CH:34][CH:33]=[CH:32][C:31]=2[S:36][CH3:37])[CH:23]=1참가 물질
6
반응물 4
생성물 2
실험 절차
4-Fluoro-2-(2-methylsulfanylphenoxy)-1-nitrobenzene (1.06 g, 68%) was prepared from 2-hydroxythioanisole (0.77 g, 5.5 mmol) and 2,5-difluoro-1-nitro-benzene (0.80 g, 5.0 mmol) following the general procedure A. This was reduced to 4-fluoro-2-(2-methanesulfanyl-phenoxy)-phenylamine (0.52 g, 62%) following general procedure C. 1-[4-Fluoro-2-(2-methylsulfanyl-phenoxy)-phenyl]-3-thiazol-2-yl-urea (117 mg, 60%) was prepared from 4-fluoro-2-(2-methylsulfanylphenoxy)aniline (125 mg, 0.5 mmol) and 2-aminothiazole (60 mg, 0.6 mmol) following the general procedure D.
출처 및 근거
- ORD 기록
- ord-f14ff09ebf6d4cb9ab7ffe272635cd7f
- 출처 데이터셋
- uspto-grants-2011_11
- 특허 번호
- US08063081B2
연결된 노트
불러오는 중…